BACKGROUND: SAMP1/Yit mice develop spontaneous, segmental, transmural ileitis recapitulating many features of Crohn's disease (CD). The ileitic phenotype may have arisen during crosses of SAMP1 mice selected for the presence of skin lesions. We hereby describe that the original SAMP1 strain similarly develops ileitis. Our aim was to characterize the histopathological and immunological features of this model and assess its responsiveness to standard inflammatory bowel disease (IBD) therapy. METHODS: The time course of histopathological features of ileitis was assessed. Immune compartments were characterized by flow cytometry. Ileal cytokine profiles and transcription factors were determined by real-time reverse-transcription polymerase chain reaction (RT-PCR). Finally, response to corticosteroid therapy and its effect on immune compartments and cellularity was evaluated. RESULTS: Histological features and time course of disease were conserved, compared to those reported in SAMP1/Yit strains, with similar expansion of CD19+, CD4+, and CD8+ effector (CD44(high) CD62L(low)), and central memory lymphocytes (CD44(high)CD62L(high)). However, different from SAMP1/YitFc mice, analysis of ileal cytokine profiles revealed initial T(H)1 polarization followed by T(H)2-polarized profile accompanied by prominent eosinophilia during late disease. Lastly, corticosteroids attenuated ileitis, resulting in decreased lymphocyte subsets and cellularity of compartments. CONCLUSIONS: Here we report that the ileitic phenotype of SAMP1-related strains was already present in the original SAMP1 strain. By contrast, the cytokine profile within the terminal ilea of SAMP1 is distinct from the mixed T(H)1/T(H)2 profile of SAMP1/YitFc mice during late disease, as it shows predominant T(H)2 polarization. Dissemination of these strains may advance our understanding of CD pathogenesis, which in 60% of patients involves the terminal ileum.
BACKGROUND: SAMP1/Yit mice develop spontaneous, segmental, transmural ileitis recapitulating many features of Crohn's disease (CD). The ileitic phenotype may have arisen during crosses of SAMP1mice selected for the presence of skin lesions. We hereby describe that the original SAMP1 strain similarly develops ileitis. Our aim was to characterize the histopathological and immunological features of this model and assess its responsiveness to standard inflammatory bowel disease (IBD) therapy. METHODS: The time course of histopathological features of ileitis was assessed. Immune compartments were characterized by flow cytometry. Ileal cytokine profiles and transcription factors were determined by real-time reverse-transcription polymerase chain reaction (RT-PCR). Finally, response to corticosteroid therapy and its effect on immune compartments and cellularity was evaluated. RESULTS: Histological features and time course of disease were conserved, compared to those reported in SAMP1/Yit strains, with similar expansion of CD19+, CD4+, and CD8+ effector (CD44(high) CD62L(low)), and central memory lymphocytes (CD44(high)CD62L(high)). However, different from SAMP1/YitFc mice, analysis of ileal cytokine profiles revealed initial T(H)1 polarization followed by T(H)2-polarized profile accompanied by prominent eosinophilia during late disease. Lastly, corticosteroids attenuated ileitis, resulting in decreased lymphocyte subsets and cellularity of compartments. CONCLUSIONS: Here we report that the ileitic phenotype of SAMP1-related strains was already present in the original SAMP1 strain. By contrast, the cytokine profile within the terminal ilea of SAMP1 is distinct from the mixed T(H)1/T(H)2 profile of SAMP1/YitFc mice during late disease, as it shows predominant T(H)2 polarization. Dissemination of these strains may advance our understanding of CD pathogenesis, which in 60% of patients involves the terminal ileum.
Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245
Authors: S L Brandwein; R P McCabe; Y Cong; K B Waites; B U Ridwan; P A Dean; T Ohkusa; E H Birkenmeier; J P Sundberg; C O Elson Journal: J Immunol Date: 1997-07-01 Impact factor: 5.422
Authors: I J Fuss; M Neurath; M Boirivant; J S Klein; C de la Motte; S A Strong; C Fiocchi; W Strober Journal: J Immunol Date: 1996-08-01 Impact factor: 5.422
Authors: J J Lee; M P McGarry; S C Farmer; K L Denzler; K A Larson; P E Carrigan; I E Brenneise; M A Horton; A Haczku; E W Gelfand; G D Leikauf; N A Lee Journal: J Exp Med Date: 1997-06-16 Impact factor: 14.307
Authors: Eóin N McNamee; Joanne C Masterson; Paul Jedlicka; Colm B Collins; Ifor R Williams; Jesús Rivera-Nieves Journal: Gut Date: 2012-01-20 Impact factor: 23.059
Authors: Colm B Collins; Carol M Aherne; Stefan F Ehrentraut; Mark E Gerich; Eóin N McNamee; Martine C McManus; Matthew D P Lebsack; Paul Jedlicka; Tania Azam; Edwin F de Zoeten; Charles A Dinarello; Jesús Rivera-Nieves Journal: Inflamm Bowel Dis Date: 2013-08 Impact factor: 5.325
Authors: Eóin N McNamee; Joanne C Masterson; Marisol Veny; Colm B Collins; Paul Jedlicka; Fergus R Byrne; Gordon Y Ng; Jesús Rivera-Nieves Journal: J Leukoc Biol Date: 2015-01-30 Impact factor: 4.962
Authors: Joanne C Masterson; Eóin N McNamee; Paul Jedlicka; Sophie Fillon; Joseph Ruybal; Lindsay Hosford; Jesús Rivera-Nieves; James J Lee; Glenn T Furuta Journal: Am J Pathol Date: 2011-09-23 Impact factor: 4.307
Authors: Deepa Rana Jamwal; Raji V Marati; Christy A Harrison; Monica T Midura-Kiela; Vanessa R Figliuolo Paz; David G Besselsen; Fayez K Ghishan; Pawel R Kiela Journal: Inflamm Bowel Dis Date: 2020-01-06 Impact factor: 5.325
Authors: Joanne C Masterson; Eóin N McNamee; Lindsay Hosford; Kelley E Capocelli; Joseph Ruybal; Sophie A Fillon; Alfred D Doyle; Holger K Eltzschig; Anil K Rustgi; Cheryl A Protheroe; Nancy A Lee; James J Lee; Glenn T Furuta Journal: Gut Date: 2012-11-17 Impact factor: 23.059
Authors: James D Nolin; H Luke Ogden; Ying Lai; William A Altemeier; Charles W Frevert; James G Bollinger; Gajendra S Naika; Anthony Kicic; Stephen M Stick; Gerard Lambeau; William R Henderson; Michael H Gelb; Teal S Hallstrand Journal: Am J Respir Cell Mol Biol Date: 2016-12 Impact factor: 6.914
Authors: Joanne C Masterson; Kelley E Capocelli; Lindsay Hosford; Kathryn Biette; Eóin N McNamee; Edwin F de Zoeten; Rachel Harris; Shahan D Fernando; Paul Jedlicka; Cheryl Protheroe; James J Lee; Glenn T Furuta Journal: Inflamm Bowel Dis Date: 2015-10 Impact factor: 5.325